LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 115 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q2 2021. The put-call ratio across all filers is 0.65 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $115,361 | +203.9% | 81,816 | +223.3% | 0.00% | – |
Q1 2023 | $37,959 | +5.8% | 25,306 | -17.5% | 0.00% | – |
Q4 2022 | $35,875 | -97.3% | 30,662 | -94.3% | 0.00% | -100.0% |
Q4 2021 | $1,325,000 | -9.5% | 540,824 | -6.9% | 0.00% | 0.0% |
Q3 2021 | $1,464,000 | -60.9% | 580,788 | -55.8% | 0.00% | -62.5% |
Q2 2021 | $3,747,000 | +27.1% | 1,314,567 | +4.8% | 0.01% | 0.0% |
Q1 2021 | $2,948,000 | +206.1% | 1,254,531 | +129.3% | 0.01% | +166.7% |
Q4 2020 | $963,000 | +388.8% | 547,215 | +160.6% | 0.00% | +200.0% |
Q3 2020 | $197,000 | -31.1% | 210,005 | -36.2% | 0.00% | 0.0% |
Q2 2020 | $286,000 | +111.9% | 328,941 | +102.3% | 0.00% | 0.0% |
Q1 2020 | $135,000 | -57.1% | 162,633 | -54.0% | 0.00% | 0.0% |
Q4 2019 | $315,000 | -3.4% | 353,705 | +6.2% | 0.00% | 0.0% |
Q3 2019 | $326,000 | – | 333,095 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $41,223,872 | 3.66% |
Raffles Associates | 1,587,739 | $1,873,532 | 2.48% |
Defender Capital, LLC. | 5,184,510 | $6,117,722 | 2.22% |
Prescott General Partners LLC | 1,851,851 | $2,185,184 | 0.14% |
DCF Advisers, LLC | 82,751 | $97,646 | 0.05% |
Beirne Wealth Consulting Services, LLC | 45,000 | $63,450 | 0.05% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $922,484 | 0.02% |
Fort Sheridan Advisors LLC | 83,931 | $99,039 | 0.02% |
MAI Capital Management | 954,688 | $1,126,532 | 0.02% |
Piscataqua Savings Bank | 12,499 | $14,623 | 0.01% |